Circulating immune- and inflammation-related biomarkers and early-stage noncardia gastric cancer risk
Authors:
- 8 July 2021
- journal article
- research article
- Published by Wolters Kluwer Health in European Journal Of Cancer Prevention
- Vol. 31 (3) , 270-273
Abstract
Background: In Helicobacter pylori-driven gastric cancer, mucosal colonization induces chronic inflammation that may variably progress to cancer. Prospective studies of circulating inflammation-related proteins have suggested weak associations with gastric cancer risk. To assess potential utility as a screening tool in clinical settings, we examined circulating levels of a wide range of key inflammation molecules for associations with early-stage gastric cancer. Methods: We used pretreatment EDTA plasma from 239 individuals with early-stage noncardia gastric cancer (203 stage I and 36 stage II) and 256 age-frequency-matched H. pylori-seropositive cancer-free controls within the Hospital-based Epidemiologic Research Program at Aichi Cancer Center. Levels of 92 biomarkers were measured by proximity extension assays using Olink’s Proseek Immuno-oncology Panel. Odds ratios (ORs) for association with gastric cancer risk were calculated for quantiles (two to four categories) of each biomarker from unconditional logistic regression models, adjusted for age, sex, smoking and alcohol consumption. Two-sided P values P-trend = 0.02) and ADGRG1 (per quartile OR, 0.84; nominal P-trend = 0.03) were associated with early-stage gastric cancer but were not statistically significant after FDR correction. Conclusion: Our study did not identify any inflammation-related biomarkers that may be useful for early disease detection. To date, this is the first assessment of circulating inflammation-related proteins in early-stage gastric cancer. Given the complex inflammation processes preceding malignant transformation, further investigation of other biomarkers is warranted.Keywords
This publication has 9 references indexed in Scilit:
- Associations of circulating mediators of inflammation, cell regulation and immune response with esophageal squamous cell carcinomaJournal of Cancer Research and Clinical Oncology, 2021
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesCA: A Cancer Journal for Clinicians, 2021
- Prediagnostic circulating inflammation biomarkers and esophageal squamous cell carcinoma: A case–cohort study in JapanInternational Journal of Cancer, 2019
- Circulating Inflammation Markers and Risk of Gastric and Esophageal Cancers: A Case–Cohort Study Within the Japan Public Health Center–Based Prospective StudyCancer Epidemiology, Biomarkers & Prevention, 2019
- Circulating inflammatory markers and colorectal cancer risk: A prospective case‐cohort study in JapanInternational Journal of Cancer, 2018
- Five-year survival analysis of surgically resected gastric cancer cases in Japan: a retrospective analysis of more than 100,000 patients from the nationwide registry of the Japanese Gastric Cancer Association (2001–2007)Gastric Cancer, 2017
- Circulating cytokines and gastric cancer riskCancer Causes & Control, 2013
- Plasma levels of C-reactive protein and serum amyloid A and gastric cancer in a nested case-control study: Japan Public Health Center-based prospective studyCarcinogenesis, 2010
- A Model of Practical Cancer Prevention for Out-patients Visiting a Hospital: the Hospital-based Epidemiologic Research Program at Aichi Cancer Center (HERPACC).2000